Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
CuraXN Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
CuraXN: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Orbitazine fumarate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
Orbitazine fumarate: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Gunagratinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
Gunagratinib: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
89Zr-trastuzumab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
89Zr-trastuzumab: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
PD-DP-008 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
PD-DP-008: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
TH-9619 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
TH-9619: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
PR-006 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
PR-006: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
ALETA-001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
ALETA-001: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Gamma-PN3 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
Gamma-PN3: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
PRA-052 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
PRA-052: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
DI-Leu16-IL2 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
DI-Leu16-IL2: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
ART-5803 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
ART-5803: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.